Literature DB >> 1681646

Evaluation of the fluorescent treponemal antibody-absorption (FTA-Abs) test specificity.

B Carlsson1, H S Hanson, J Wasserman, A Brauner.   

Abstract

Serum samples from 43 patients with positive test for syphilis only in the FTA-Abs test, were evaluated. Three had primary or treated syphilis. Twenty-one (49%) had clinical and/or serological signs of Lyme borreliosis as assessed by whole-cell sonicate Borrelia burgdorferi ELISA and Western blot techniques. Seven (16%) had genital Herpes simplex infection and the remaining 12 patients, miscellaneous disorders. In control sera from 30 patients with Lyme borreliosis an isolated positive FTA-Abs reaction was found in 13 patients (43%). Elevated Borrelia ELISA titres were found in nine of 30 (30%) syphilitic patient serum samples, whereas Western blots for Borrelia were negative. Six per cent of healthy blood donors were seropositive for Borrelia. Lyme borreliosis is an important cause of cross-reactions in the FTA-Abs test. Other serological tests for syphilis and Western blot for Borrelia are useful for discrimination.

Entities:  

Mesh:

Year:  1991        PMID: 1681646

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  4 in total

1.  Validation of the INNO-LIA syphilis kit as a confirmatory assay for Treponema pallidum antibodies.

Authors:  A Ebel; L Vanneste; M Cardinaels; E Sablon; I Samson; K De Bosschere; F Hulstaert; M Zrein
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Guidelines for serological testing for syphilis.

Authors:  H Young
Journal:  Sex Transm Infect       Date:  2000-10       Impact factor: 3.519

Review 3.  Syphilis in pregnancy.

Authors:  M Genç; W J Ledger
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

4.  Comparison of RPR and ELISA with TPHA for the Diagnosis of Syphilis: Implication for Updating Syphilis Point-of-Care Tests in Ethiopia.

Authors:  Markos Negash; Tadelo Wondmagegn; Demeke Geremew
Journal:  J Immunol Res       Date:  2018-07-08       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.